POZRectal Douching Linked to Higher Risk of HIV, STIs, Hep B and C in Gay Men
AIDSMAP ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available
AIDSMAP Just 18% of people with hepatitis/HIV co-infection and cirrhosis are screened for liver cancer as often as recommended NPR Expert Panel Recommends Wider Use Of Daily Pill To Prevent HIV Infections
POZ Very Early HIV Treatment May Preserve Key Immune Responses to Virus – Researchers compared the immune systems of South African women who started treatment at different points postinfection.
POZHigh STI Rate Among Some PrEP Users Suggests Need for Frequent Testing – A quarter of study participants accounted for three-quarters of newly diagnosed cases of chlamydia, gonorrhea and syphilis
POZ Early Studies of HIV Maturation Inhibitor Shows It’s Safe and Tolerable – ViiV Healthcare and GlaxoSmithKline are jointly developing GSK3640254.
ScienceDaily In rare cases, immune system fails despite HIV suppression – Scientists identify paradoxical response to HIV medication in five individuals
POZ New Combo (genamicin + azithromycin) Could Work as Backup Treatment for Drug-Resistant Gonorrhea (however, it does not work as well as current therapy for rectal or throat infections)
POZ New Antibody Shows Promise as Long-Acting HIV Treatment: A series of antibody infusions suppressed HIV for up to four months without prompting the virus to develop resistance.
POZ A Growing Number of People With HIV Have Fatty Liver Disease: The number of HIV-positive Medicare recipients with liver disease is rising, almost entirely as a result of NAFLD
Rapid Initiation of Symtuza for HIV Treatment Shows Promise (editorial note: however, protease inhibitors have higher rates of ASCVD and thousands of drug-drug interactions) – more from MDAlert
Updated DHHS Guidelines late 2018 agree with previous IAS recommendations: 1. A combined analysis of European cohorts,16,66 a small randomized trial,67 and a case series68 found a low incidence of PCP in patients with CD4 counts between 100 cells/mm3 and 200 cells/mm3, who were receiving ART and had HIV plasma viral loads <50 to 400 copies/mL, and who had stopped or never received PCP prophylaxis, suggesting that primary and secondary PCP prophylaxis can be safely discontinued in patients with CD4 counts between 100 cells/mm3 to 200 cells/mm3 and HIV plasma RNA levels below limits of detection of commercial assays. Data on which to base specific recommendations are inadequate, but one approach would be to stop primary prophylaxis in patients with CD4 counts of 100 cells/mm3 to 200 cells/mm3 if HIV plasma RNA levels remain below limits of detection for ≥3 months to 6 months (BII). Similar observations have been made with regard to stopping primary prophylaxis for Toxoplasma encephalitis.69 2. Primary prophylaxis against disseminated MAC disease is not recommended for adults and adolescents with HIV who immediately initiate ART (AII). People with HIV who are not receiving ART or who remain viremic on ART but have no current options for a fully suppressive ART regimen should receive chemoprophylaxis against disseminated MAC disease if they have CD4 counts <50 cells/mm3(AI). Primary MAC prophylaxis, if previously initiated, should be discontinued in adults and adolescents who are continuing on a fully suppressive ART regimen (AI). Two randomized, placebo-controlled trials and observational data have demonstrated that people with HIV taking ART can discontinue primary prophylaxis with minimal risk of developing MAC disease.36-4
CROI 2019 Gay & Bi Men With HIV Cured of Hep C Are Reinfected at High Rate
CROI 2019 Early Trial of Gilead’s HIV Capsid Inhibitor Supports 3-Month Dosing
CROI 2019 The Viral Reservoir (or cellular clonal expansion) Can Explain Persistent Low Level Viremia With Good Adherence on ART. POZ has another post on this issue.
CROI 2019 Neural tube defects and integrase inhibitors: still waiting for stronger evidence
CROI 2019 Study Highlights Link Between ART and Weight Gain in Virally Suppressed Participants
CROI 2019 Researchers report high rate of viral suppression among people new to HIV care
CROI 2019 Individuals With HIV May Be at Higher Risk of Opioid Overdose Death
CROI 2019 Depo injection cabotegravir + rilpivirine found to be noninferior at 48 weeks to 3-drug oral ART as well as to dolutegravir/abacavir/lamivudine
CROI 2019 TAF/emtricitabine appears to be noninferior to TDF/emtricitabine in MSM, transgender women for PrEP
CROI 2019 HIV is a risk for cardiac death if the HIV viral load is not suppressed
CROI 2019 A second patient who has received an HIV-resistant bone marrow transplant may be cured of HIV (the famous “Berlin” patient is the first one). More detailed info from theBody.com
